Abstract
Purpose
European Patient Advocacy Groups (ePAGs) within the Endo-ERN identified a lack of knowledge about quality of care (QoC) of patients with multiple endocrine neoplasia (MEN). The aim of this study was to identify inequalities in care and to encourage improvements.
Methods
The European MEN Alliance (EMENA) developed and conducted a survey, using the European Commissions’ EUSurvey platform. Patient groups and healthcare professionals (HCPs) distributed the survey.
Results
A total of 288 participants completed the survey (MEN1 n = 203, MEN2 n = 67, MEN3 n = 18) from 18 European countries. The majority of respondents were recruited via patient groups (58%), aged between 41 and 60 years (53%) and were female (67%). All participants reported having been diagnosed on average 5.58 years (95%-CI: 4.45–6.60) after first symptoms occurred. This timeframe was lower in the group with MEN2 (2.97 years, 95%-CI: 1.37–4.57). Most of the participants (67%) received their diagnosis by a positive gene test after presenting with one or more MEN-related tumours. Overall QoC was rated as either “good” (43%) or “excellent” (36%).
Conclusion
The results of this unique Europe-wide, patient-driven survey on QoC of patients with MEN show that ratings for overall QoC were lower than ratings for different aspects of care. This may be because of the complex nature of care for genetic syndromes. Furthermore, patients who connect with patient groups may be deemed “expert patients” whose answers are not representative of the overall MEN patient community. We hope that Endo-ERN can support further education and training for HCPs based on these results.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Multiple endocrine neoplasia (MEN) syndromes cause a genetic predisposition in a person to develop tumours involving at least two endocrine glands. Until now, four types of MEN disorders have been identified, called MEN1, MEN2 (formerly MEN2a), MEN3 (formerly MEN2b) and MEN4 (also known as MENX). Each syndrome is characterised by the occurrence of different tumours over time. Parathyroid, pituitary and pancreatic islet cell tumours regularly occur in MEN1. Parathyroid hyperplasia, medullary thyroid carcinoma (MTC) and pheochromocytoma are specific for MEN2. MTC, pheochromocytoma and a Marfanoid appearance in MEN3. MEN4 is characterized with parathyroid and anterior pituitary tumours in connection with tumours of the kidneys, adrenals and the reproductive system. All MEN syndromes are inherited as autosomal dominant disorders [1,2,3,4,5,6,7,8,9,10,11,12]. MEN1 is the result of a gene mutation on chromosome 11q13 of the “Menin” gene, while MEN2 is characterized by a failure of the “rearranged during transfection” (RET) gene [13,14,15]. Most of the studies published so far focus on genetics [2, 3, 16,17,18,19], screening and diagnostics [20, 21] or therapeutic aspects [4, 5, 22, 23]. A few studies report on quality of life [22, 24,25,26,27,28,29,30] but there have been no studies so far on quality of care (QoC) in MEN patients. However, patients and patient groups are interested in QoC and equality of care throughout Europe. Patient-oriented research is important and currently on the rise [31,32,33]. So far, there is no concrete, verifiable evidence of their benefit [34]. Nevertheless, patient-driven research, particularly in rare diseases, can contribute to faster research because of the “unique motivations and research approach[es]” [35] of patient groups.
The establishment of the European Reference Networks (ERNs) for Rare Diseases, including the European Reference Network on Rare Endocrine Conditions (Endo-ERN) in 2017, was intended to improve the care of rare disease patients living in the European Union. This requires an assessment of the current status, the needs and the differences in the care of patients with MEN syndromes that goes beyond anecdotal description. For example, which components of care are successful in one country and could improve care in another country? In the MTG 4 (main thematic group “Genetic Endocrine Tumour Syndromes”) of the Endo-ERN, country-specific differences in care have been identified, for example, in the development of guidelines.
The objective of our project was to perform a first investigation of patient-reported perceived QoC in MEN syndromes in Europe through a patients for patients research approach.
Materials and methods
In a participatory process, members (mostly patient advocates) of the multinational umbrella group, European Multiple Endocrine Neoplasia Alliance (EMENA), developed an online questionnaire to gather patient-reported aspects on perceived QoC. This unique questionnaire contained 29 questions in sections about sociodemographics, participants’ disease experience, access and use of healthcare services, trust, adherence, decision-making and satisfaction with care in general. The questionnaire was designed by patients for patients. Afterwards, we performed paper-based and online pre-tests regarding the feasibility of the survey. Volunteer native speakers of several patient groups translated our final English draft into French, Spanish, Italian, Dutch and German languages. We chose this approach to harness the familiarity of these individuals with the specific medical terminology in their language. We implemented the final version of the survey on the European Commissions’ EUSurvey platform [36]. Distribution of the survey was done through EMENA national member groups in the UK, Belgium, The Netherlands, Italy and Germany and affiliated groups in France, as well as through Endo-ERN European Patient Advocacy Groups and other rare diseases associations in all EU-28 countries, mostly via mailing lists, social media or other online channels. We conducted the survey between March and May 2018. Informed consent was obtained by every participant in advance by actively agreeing on the terms of the survey. In case of patients younger than 18 years, we encouraged the legal guardians to complete the survey on their behalf. The survey was conducted anonymously. We did not collect any data that would allow us to identify any individual participant. If there were fewer than five participants from one country, we did not consider these cases individually for further analysis but have grouped them under “other countries”.
Variables used for analyses
The variables considered for our analyses can be found in Table 1.
Data management and analyses
We extracted and downloaded data from the EUSurvey platform and performed data cleaning afterwards. We checked our data for plausibility by using the “unusual cases” function in SPSS and completed further checks on consistency of the data. Information on the timespan from symptoms to diagnosis was limited to 40 years, resulting in three implausible values (50/100/100 years) which were set to missing as no clarification was possible due to anonymization. No further exclusions or corrections had to be made. Statistical analyses were undertaken using SAS 9.0 (SAS Institute, Cary NC, USA) and SPSS 25 (IBM, Armonk NY, USA). We computed point and interval estimates with respective confidence intervals, where appropriate. We did not perform any formal hypothesis testing due to the nature of our survey.
Results
Characteristics of the study population
A total of 288 participants completed the survey (MEN1 n = 203, MEN2a n = 67, MEN2b/3 n = 18) from 18 European countries (36% UK, 19% Italy, 16% The Netherlands, 12% Germany, 7% France, 10% other). The majority of respondents were female (67%) and knew about the survey via patient groups (58%). Participants were aged between 0 and 70+ years old and the majority (53%) were aged 41–60 years. There were no differences by gender regarding age. More characteristics by type of MEN disorder are shown in Table 2.
Diagnoses of MEN
All participants reported to have been diagnosed on average 5.4 years (95%-CI: 4.5–6.6) after first symptoms occurred. This mean timespan was shorter in the group with MEN2 (2.9 years, 95%-CI: 1.4–4.6), more details are shown in Table 3. There was also a shorter mean timespan among participants with a previous positive family history and a therefore performed gene test: 3.1 years (95%-CI: 1.6–4.6) vs. 6.1 years (4.9–7.3). Most of the participants (67%) were diagnosed by a positive gene test after presenting with one or more MEN-related tumour. More women than men (68%) were among all participants affected by MEN disorders (56% in MEN3 patients).
Perception of QoC
Participants were mainly treated by an endocrinologist (77%) in a specialist reference centre (65%). Only 42% reported having access to a specialist endocrine nurse. This percentage differed widely between European countries, see Table 4. Most participants reported having just the right amount of time to talk to their doctor about their MEN care (73%), felt listened to (85%) and felt involved in decisions about their care (81%). The majority believed that their medical team was well informed about MEN (84%) and trusted their medical team (85%). Regional differences are shown in Table 4. Overall QoC was rated as either “good” (43%) or “excellent” (36%). Results for MEN1 differed slightly from those for MEN2 or MEN3 (“excellent” 25% vs. 40 and 44%, respectively; “good” 46% vs. 30 and 50%, respectively). Further reported quality indicators are shown in Table 4.
Discussion
To our knowledge, this is the first study about QoC aspects in MEN syndromes in Europe. We present findings of an online survey among 288 participants from 18 different European countries who were recruited via patient groups all over Europe using different methods. We developed and translated our survey among our multinational umbrella patient group. Even though our questionnaire has not been validated, we believe that our approach to analyse the QoC of MEN patients is a valuable first step in bringing about improvements in care for MEN patients.
In line with previous findings [37, 38], more women than men engage with patient advocacy groups and actively take part in surveys, so more females than males are represented in our survey.
The lower timespan from first symptoms to diagnosis in MEN2 patients (3 years) vs. MEN1 patients (6 years) might be a result of completely different courses of the diseases and diagnostic approaches, respectively: in MEN2, a thyroid screening usually reveals nodules that are quickly identified as cold nodules using a scintigram. Because this is a tumour disease, these patients are assessed much more thoroughly and this might lead to an earlier diagnosis of MEN2 [5, 26]. On the other hand, the clinical picture of MEN1 is much more varied, and at the beginning of the disease, before the exact diagnosis is made, it points to many more different clinical pictures [2]. The lower timespan from first symptoms to diagnosis in patients with a positive family history (3 vs. 6 years) can certainly be explained in part by genetic testing. We were not able to determine why it still takes an average of 3 years until a diagnosis is made in this group.
The trend for lower ratings regarding the overall QoC by participants with MEN1 might be connected to a perceived longer “diagnostic odyssey” in MEN1. Patients need to consult many different healthcare specialists (internists, endocrinologists, oncologists, gastroenterologists) up to their diagnosis. These ratings could further be related to the fact that patients do not feel they are taken seriously enough during this “odyssey”.
Access to a specialist endocrine nurse varies widely between different countries, most probably due to different health systems. Specialist endocrine nurses are an important link between doctors and patients to support patients along their complex path through medical care not only medically but also emotionally and psychologically [39]. As there is no evidence on availability of endocrine nurses in Europe or a comparison between EU member states, it is speculative to discuss those differences. However, specialist nurses are, in general, considered to contribute to a higher patient satisfaction [40].
Unfortunately, contrary to our expectations, the response rate from Spain and Portugal was low, although local patient representatives were highly committed to promote our survey. No citizens of eastern European countries participated in our survey, as the patient organizations are rare or non-existent and language barriers are still a major challenge. Therefore, we already see this underrepresentation as a further indication of the inequality in the care of MEN patients across Europe. We hope that with the increasing establishment and expansion of Endo-ERN, cooperation with the patients there can be established.
Uniqueness of our project
This research project was planned and conducted in a participatory process driven by patients, supported by doctors and scientists from several European countries. Our collaborative project of patient groups across Europe on a rare disease topic seems to be exclusive so far as research was conducted from patients about patients for patients.
Conclusion
This project shows that MEN patients in Europe generally consider the quality of their care to be of a high standard. Depending on the type of endocrine disorder, differences in the perception of QoC could be taken into account when updating medical guidelines. However, qualitative research might be necessary to investigate further aspects regarding the patients’, their relatives’ and healthcare professionals’ perspectives on this matter. Our pan-European project might encourage clinicians and scientists across Europe to further intensify their cooperation in research on MEN. The setting up of the European Registries for Rare Endocrine Conditions project within the Endo-ERN is an important first step. As these tumour syndromes are rare, there are always only a few patients per country or study centre. It is important to take advantage of the opportunities offered by cross-border cooperation. In particular, the establishment and integration of the Endo-ERN network structure into the respective national healthcare systems might lead to improvements in the care of MEN patients and also to a harmonization of the QoC on a common wider European level.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
R.V. Thakker, Multiple endocrine neoplasia-syndromes of the twentieth century. J. Clin. Endocrinol. Metab. 83(8), 2617–2620 (1998)
R.V. Thakker, Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol. Cell Endocrinol. 386(1–2), 2–15 (2014). https://doi.org/10.1016/j.mce.2013.08.002
M.C. Pacheco, Multiple endocrine neoplasia: a genetically diverse group of familial tumor syndromes. J. Pediatr. Genet. 5(2), 89–97 (2016). https://doi.org/10.1055/s-0036-1579758
G.V. Walls, Multiple endocrine neoplasia (MEN) syndromes. Semin. Pediatr. Surg. 23(2), 96–101 (2014). https://doi.org/10.1053/j.sempedsurg.2014.03.008
J.E. McDonnell, M.L. Gild, R.J. Clifton-Bligh, B.G. Robinson, Multiple endocrine neoplasia: an update. Intern. Med. J. 49(8), 954–961 (2019). https://doi.org/10.1111/imj.14394
F. Marini, A. Falchetti, F. Del Monte, S. Carbonell Sala, A. Gozzini, E. Luzi, M.L. Brandi, Multiple endocrine neoplasia type 1. Orphanet J. Rare Dis. 1, 38 (2006)
F. Marini, A. Falchetti, F. Del Monte, S. Carbonell Sala, I. Tognarini, E. Luzi, M.L. Brandi, Multiple endocrine neoplasia type 2. Orphanet J. Rare Dis. 1, 45 (2006)
A. Falchetti, F. Marini, E. Luzi, F. Giusti, L. Cavalli, T. Cavalli, M.L. Brandi, Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet. Med. 11(12), 825–835 (2009)
J. Moline, C. Eng, Multiple endocrine neoplasia type 2: an overview. Genet. Med. 13(9), 755–764 (2011). https://doi.org/10.1097/GIM.0b013e318216cc6d
J.T. Pang, R.V. Thakker, Multiple endocrine neoplasia type 1 (MEN1). Eur. J. Cancer 30A(13), 1961–1968 (1994)
A. Calender, P. Goudet, Multiple endocrine neoplasia type 1. MEN1—Wermer syndrome. Ann. Endocrinol. 64(5 Pt 1), 383–388 (2003).
A.F. Scarsbrook, R.V. Thakker, J.A. Wass, F.V. Gleeson, R.R. Phillips, Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. Radiographics 26(2), 433–451 (2006)
F. Khatami, S.M. Tavangar, Multiple endocrine neoplasia syndromes from genetic and epigenetic perspectives. Biomark. Insights 13, 1177271918785129 (2018). https://doi.org/10.1177/1177271918785129
S.C. Chandrasekharappa, S.C. Guru, P. Manickam, S.E. Olufemi, F.S. Collins, M.R. Emmert-Buck, L.V. Debelenko, Z. Zhuang, I.A. Lubensky, L.A. Liotta, J.S. Crabtree, Y. Wang, B.A. Roe, J. Weisemann, M.S. Boguski, S.K. Agarwal, M.B. Kester, Y.S. Kim, C. Heppner, Q. Dong, A.M. Spiegel, A.L. Burns, S.J. Marx, Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276(5311), 404–407 (1997). https://doi.org/10.1126/science.276.5311.404
L.M. Mulligan, B.A. Ponder, Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J. Clin. Endocrinol. Metab. 80(7), 1989–1995 (1995). https://doi.org/10.1210/jcem.80.7.7608246
L. Schaaf, J. Pickel, K. Zinner, U. Hering, M. Hofler, P.E. Goretzki, F. Spelsberg, F. Raue, A. von zur Muhlen, H. Gerl, J. Hensen, D.K. Bartsch, M. Rothmund, U. Schneyer, H. Dralle, M. Engelbach, W. Karges, G.K. Stalla, W. Hoppner, Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp. Clin. Endocrinol. Diabetes 115(8), 509–517 (2007)
M.C. Lemos, R.V. Thakker, Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 29(1), 22–32 (2008)
A. Machens, L. Schaaf, W. Karges, K. Frank-Raue, D.K. Bartsch, M. Rothmund, U. Schneyer, P. Goretzki, F. Raue, H. Dralle, Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin. Endocrinol. 67(4), 613–622 (2007)
J.M. de Laat, R.B. van der Luijt, C.R. Pieterman, M.P. Oostveen, A.R. Hermus, O.M. Dekkers, W.W. de Herder, A.N. van der Horst-Schrivers, M.L. Drent, P.H. Bisschop, B. Havekes, M.R. Vriens, G.D. Valk, MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med. 14(1), 182 (2016). https://doi.org/10.1186/s12916-016-0708-1
W. Karges, L. Schaaf, H. Dralle, B.O. Boehm, Concepts for screening and diagnostic follow-up in multiple endocrine neoplasia type 1 (MEN1). Exp. Clin. Endocrinol. Diabetes 108(5), 334–340 (2000)
J. Waldmann, V. Fendrich, N. Habbe, D.K. Bartsch, E.P. Slater, P.H. Kann, M. Rothmund, P. Langer, Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J. Surg. 33(6), 1208–1218 (2009)
S. Goswami, B.J. Peipert, I. Helenowski, S.E. Yount, C. Sturgeon, Disease and treatment factors associated with lower quality of life scores in adults with multiple endocrine neoplasia type I. Surgery 162(6), 1270–1277 (2017). https://doi.org/10.1016/j.surg.2017.07.023
C.J. Yates, P.J. Newey, R.V. Thakker, Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol. 3(11), 895–905 (2015). https://doi.org/10.1016/S2213-8587(15)00043-1
F.A. Correa, E.C. Farias, L.A. Castroneves, D.M. Lourenco Jr., A.O. Hoff, Quality of life and coping in multiple endocrine neoplasia type 2. J. Endocr. Soc. 3(6), 1167–1174 (2019). https://doi.org/10.1210/js.2018-00371
A. Falchetti, F. Marini, F. Tonelli, M.L. Brandi, Lessons from genes mutated in multiple endocrine neoplasia (MEN) syndromes. Ann. Endocrinol. 66(3), 195–205 (2005)
J. Grey, K. Winter, Patient quality of life and prognosis in multiple endocrine neoplasia type 2. Endocr.-Relat. Cancer 25(2), T69–T77 (2018). https://doi.org/10.1530/ERC-17-0335
B.J. Peipert, S. Goswami, I. Helenowski, S.E. Yount, C. Sturgeon, Financial burden is associated with worse health-related quality of life in adults with multiple endocrine neoplasia type 1. Surgery 162(6), 1278–1285 (2017). https://doi.org/10.1016/j.surg.2017.07.010
M.N. Mongelli, B.J. Peipert, S. Goswami, I. Helenowski, S.E. Yount, C. Sturgeon, Quality of life in multiple endocrine neoplasia type 2A compared with normative and disease populations. Surgery 164(3), 546–552 (2018). https://doi.org/10.1016/j.surg.2018.04.036
B.J. Peipert, S. Goswami, S.E. Yount, C. Sturgeon, Health-related quality of life in MEN1 patients compared with other chronic conditions and the United States general population. Surgery 163(1), 205–211 (2018). https://doi.org/10.1016/j.surg.2017.04.030
R.S. van Leeuwaarde, C.R.C. Pieterman, E.M.A. Bleiker, O.M. Dekkers, A.N. van der Horst-Schrivers, A.R. Hermus, W.W. de Herder, M.L. Drent, P.H. Bisschop, B. Havekes, M.R. Vriens, G.D. Valk, High fear of disease occurrence is associated with low quality of life in patients with multiple endocrine neoplasia type 1: results from the Dutch MEN1 Study Group. J. Clin. Endocrinol. Metab. 103(6), 2354–2361 (2018). https://doi.org/10.1210/jc.2018-00259
N. Frisch, P. Atherton, M.M. Doyle-Waters, M.L.P. MacLeod, A. Mallidou, V. Sheane, J. Ward, J. Woodley, Patient-oriented research competencies in health (PORCH) for researchers, patients, healthcare providers, and decision-makers: results of a scoping review. Res. Involv. Engagem. 6, 4 (2020). https://doi.org/10.1186/s40900-020-0180-0
J. Hanefeld, T. Powell-Jackson, D. Balabanova, Understanding and measuring quality of care: dealing with complexity. Bull. World Health Organ 95(5), 368–374 (2017). https://doi.org/10.2471/BLT.16.179309
A. Bowling, G. Rowe, N. Lambert, M. Waddington, K.R. Mahtani, C. Kenten, A. Howe, S.A. Francis, The measurement of patients’ expectations for health care: a review and psychometric testing of a measure of patients’ expectations. Health Technol. Assess. 16(30), (2012). https://doi.org/10.3310/hta16300
L.P. Forsythe, V. Szydlowski, M.H. Murad, S. Ip, Z. Wang, T.A. Elraiyah, R. Fleurence, D.H. Hickam, A systematic review of approaches for engaging patients for research on rare diseases. J. Gen. Intern. Med. 29(3), 788–800 (2014). https://doi.org/10.1007/s11606-014-2895-9
G.R. Polich, Rare disease patient groups as clinical researchers. Drug Discov. Today 17(3-4), 167–172 (2012). https://doi.org/10.1016/j.drudis.2011.09.020
European Commission. EU Survey. 2020. https://ec.europa.eu/eusurvey/home/welcome
K.J. Johnson, N.L. Mueller, K. Williams, D.H. Gutmann, Evaluation of participant recruitment methods to a rare disease online registry. Am. J. Med. Genet. Part A 164(7), 1686–1694 (2014). https://doi.org/10.1002/ajmg.a.36530
A.L. Crowe, A.J. McKnight, H. McAneney, Communication needs for individuals with rare diseases within and around the healthcare system of Northern Ireland. Front. Public Health 7(236), (2019). https://doi.org/10.3389/fpubh.2019.00236
M. Tadman, L. Martin, Multiple endocrine neoplasia. in Advanced Practice in Endocrinology Nursing, ed. by S. Llahana, C. Follin, C. Yedinak, A. Grossman (Springer International Publishing, Cham, 2019), pp. 1259–1278
M. Ruggeri, C. Drago, V. Moramarco, S. Coretti, J. Köppen, M.K. Islam, J. Gibson, R. Busse, J. van Exel, M. Sutton, J.E. Askildsen, C.M. Bond, R.F. Elliott, New professional roles and patient satisfaction: evidence from a European survey along three clinical pathways. Health Policy 122(10), 1078–1084 (2018). https://doi.org/10.1016/j.healthpol.2018.07.020
Acknowledgements
The authors would like to thank the European Commission for the EUSurvey platform used. The authors kindly acknowledge the support of EMENA’s Medical Advisory Board, particularly Paul Newey (Dundee, UK), Rajesh Thakker (Oxford, UK) and Gerlof Valk (Utrecht, The Netherlands). Furthermore, the authors highly appreciate the support of Endo-ERN co-chairs Alberto Pereira (Leiden, The Netherlands) and Olaf Hiort (Lübeck, Germany).
Funding
EURORDIS - Rare Diseases Europe (Paris, France) partially funded the project’s initial planning meeting.
Author information
Authors and Affiliations
Contributions
K.P.D. performed data analysis, interpreted the results and wrote the manuscript. P.B., J.G. and L.S. contributed to the interpretation of the results and to writing the manuscript. K.P.D., P.B., J.G., J.P., M.S., M.A., D.v.G. and L.S. had the idea for the project and designed the questionnaire. J.P. and M.-L.B. contributed to interpreting the results and writing the manuscript. All authors reviewed the manuscript and approved it for submission.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest. J.G. and P.B. are European Patient Advocacy Group patient representatives and co-chairs of the main thematic group (MTG) 4 (Genetic Endocrine Tumour Syndromes) of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).
Ethics statement
The multinational umbrella group, European Multiple Endocrine Neoplasia Alliance (EMENA), planned and executed this study as a collaborative way for the various patient groups (EMENA members) to assess patients’ perspectives on quality of care rather than as an academic or medical research study. The authors therefore did not seek ethics approvals. The authors did not collect personal data of participants that would allow them to identify participants despite their topic being about rare diseases. All participants were asked for their consent to publish the results of the survey. The data collection covers 18 out of the 28 EU member states primarily due to the lack of participatory patient representation in some countries. The authors collected anonymized data thus complying with EU General Data Protection Regulations.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Drewitz, K.P., Grey, J., Brügmann, P. et al. Patients’ perception on the quality of care for multiple endocrine neoplasia disorders in Europe: an online survey from a patient support group. Endocrine 71, 634–640 (2021). https://doi.org/10.1007/s12020-021-02637-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-021-02637-w